Filing Flows

Filing Flows › Caris Life Sciences (CAI) › Q2 2026

Caris Life Sciences (CAI) Q2 2026 earnings results (second quarter 2026)

10-Q filed Aug 5, 2026

Caris Life Sciences (CAI) reported revenue of $264M for the second quarter 2026 (Q2 2026), +45% from a year earlier and +22% from the quarter before. Operating margin was 10.2%, net loss $637K (0.2% of revenue).

Revenue$264M
Year over year+45%
Quarter over quarter+22%
Operating margin10.2%
Net earnings−$637K

Caris Life Sciences, Q2 2026: revenue $264M (+45% year over year), operating margin 10.2%, net loss $637K, operating cash flow $28.5M. The chart follows the revenue to costs, profit and cash.

Q2 2026AmountQ/QY/Y
Revenue$264M+22%+45%
Operating profit$26.9M+410%—
Net earnings−$637K——
Operating cash flow$28.5M-13%+291%
Free cash flow$6.4M—+8%

What changed

Revenue was $263.7M in Q2 2026, up 45% year over year and up 22% from the previous quarter. Molecular Profiling Services was the largest line at 96% of revenue. Molecular Profiling Services added $89.3M year over year (up 55%), 109% of the total change. Pharma Research and Development Services declined 38%.

Operating profit was $26.9M, a 10.2% margin (up 20.1 points year over year). Total costs grew 19% against revenue growth of 45%. The fastest-growing cost line was Research & development (+29%). The quarter ended with a net loss of $637K, wider than the previous quarter's $510K loss. Net interest and other expense of $27.5M was the main reason.

Operating cash flow was $28.5M (up 291% year over year). Non-cash charges added back $6.5M of depreciation and amortization and $22.2M of share-based compensation. After capitalized software and purchases of property and equipment ($22.1M), free cash flow as the company reports it was $6.4M.

Questions

What was Caris Life Sciences' revenue in the second quarter 2026?

Caris Life Sciences (CAI) reported revenue of $264M for the second quarter 2026 (Q2 2026), +45% from a year earlier and +22% from the quarter before.

Was Caris Life Sciences profitable in the second quarter 2026?

Operating profit was $26.9M (10.2% of revenue) and net loss $637K.

Open the interactive Sankey →

Source: Caris Life Sciences 10-Q on SEC EDGAR.